UPDATED May 07, 2024
All the companies in the healthcare sector, including healthcare provider and equipment, healthcare tech, pharmaceuticals, biotech and life sciences.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
LLY | US$777.77 | -0.4% | 81.6% | US$700.3b | US$848.35 | PE114.1x | E27.0% | 0.7% | Pharmaceuticals & Biotech | ||
UNH | US$500.96 | 3.6% | 2.2% | US$460.9b | US$567.36 | PE30x | E19.6% | 1.5% | Healthcare | ||
JNJ | US$148.72 | 2.9% | -7.7% | US$357.9b | US$173.26 | PE21x | E7.0% | 3.3% | Pharmaceuticals & Biotech | ||
MRK | US$130.38 | 0.9% | 11.0% | US$330.2b | US$141.64 | PE143.2x | E24.9% | 2.4% | Pharmaceuticals & Biotech | ||
ABBV | US$162.55 | -0.06% | 10.7% | US$287.0b | US$182.31 | PE48.2x | E23.3% | 3.8% | Pharmaceuticals & Biotech | ||
AZN | UK£121.18 | 0.5% | 1.7% | UK£187.9b | UK£132.10 | PE37.1x | E15.7% | 2.0% | Pharmaceuticals & Biotech | ||
TMO | US$572.87 | 0.7% | 7.1% | US$218.7b | US$625.47 | PE36.2x | E10.6% | 0.3% | Pharmaceuticals & Biotech | ||
ABT | US$106.17 | 0.2% | -3.7% | US$184.7b | US$126.14 | PE32.9x | E11.3% | 2.1% | Healthcare | ||
DHR | US$248.76 | 0.9% | 5.8% | US$184.3b | US$272.68 | PE45.3x | E13.5% | 0.4% | Pharmaceuticals & Biotech | ||
AMGN | US$300.30 | 9.6% | 28.1% | US$161.1b | US$313.31 | PE42.8x | E17.8% | 3.0% | Pharmaceuticals & Biotech | ||
PFE | US$27.77 | 8.4% | -27.8% | US$157.2b | US$31.89 | PS2.9x | E29.7% | 6.0% | Pharmaceuticals & Biotech | ||
ISRG | US$388.65 | 4.9% | 28.9% | US$137.9b | US$420.38 | PE69.4x | E11.6% | n/a | Healthcare | ||
SYK | US$332.14 | -1.3% | 17.1% | US$126.5b | US$372.35 | PE37.6x | E10.5% | 1.0% | Healthcare | ||
ELV | US$536.17 | 1.4% | 16.4% | US$124.6b | US$603.15 | PE20x | E12.2% | 1.2% | Healthcare | ||
MDT | US$81.90 | 2.1% | -8.6% | US$108.7b | US$94.77 | PE25.9x | E9.7% | 3.4% | Healthcare | ||
BSX | US$73.43 | 2.2% | 38.3% | US$108.0b | US$81.17 | PE61.2x | E18.1% | n/a | Healthcare | ||
REGN | US$969.97 | 8.9% | 28.5% | US$106.9b | US$1,034.47 | PE27.7x | E12.2% | n/a | Pharmaceuticals & Biotech | ||
VRTX | US$410.24 | 4.4% | 19.0% | US$106.0b | US$461.69 | PE26.4x | E10.0% | n/a | Pharmaceuticals & Biotech | ||
CI | US$346.70 | -2.9% | 31.9% | US$98.5b | US$391.82 | PE27.2x | E17.8% | 1.6% | Healthcare | ||
GSK | UK£17.61 | 5.3% | 21.8% | UK£71.8b | UK£20.20 | PE16x | E11.9% | 3.3% | Pharmaceuticals & Biotech | ||
BMY | US$44.04 | 0.2% | -35.2% | US$89.3b | US$53.19 | PS2x | E43.8% | 5.4% | Pharmaceuticals & Biotech | ||
CSL | AU$279.56 | 1.0% | -6.8% | AU$135.1b | AU$306.40 | PE36.1x | E14.7% | 1.3% | Pharmaceuticals & Biotech | ||
HCA | US$314.45 | 1.5% | 14.7% | US$82.4b | US$344.35 | PE15.1x | E6.0% | 0.8% | Healthcare | ||
GILD | US$65.46 | 0.4% | -16.9% | US$81.6b | US$82.93 | PE168.3x | E36.5% | 4.7% | Pharmaceuticals & Biotech |